Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The city of San Diego, California, because ... with a plan to recycle wastewater – also called ... supports the San Diego plan as part of her ... Kleyne, by recycling water that San Diego already owns, ... greatly reduced. (Spagat, E, “San Diego looks to sewers ...
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 News ... showcase expanded capabilities at RSNA 2014 in Chicago. ... manage and share diagnostic images, photos, videos and ... Perceptive’s booth #8107 will learn more about these ... acquired technologies and partner initiatives – that enable ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... Shared genes point to interbreeding with modern humans , THURSDAY, ... of the Neanderthal, Homo sapiens , closest evolutionary relative, ... makes humans uniquely human. , As it turns out, 1 ... outside of Africa was probably inherited from Neanderthals, apparently because ...
... after timing change, researchers say , THURSDAY, May 6 (HealthDay ... vitamin D supplement if you take it with your largest ... examined 17 patients with vitamin D deficiency who weren,t getting ... months, the patients were told to take vitamin D supplements ...
... from Cold Spring Harbor Laboratory in the USA have developed ... tumor cells. The breakthrough allows them to study in fine ... potential to help doctors identify dangerous tumor cells from small ... non-invasive lesion in the breast. Dr James Hicks from ...
... Maria Mandalakas, MD, MSEpi, associate professor of Pediatrics, ... Western Reserve University School of Medicine, has been ... Board to receive a 2010 U.S. Fulbright Scholarship. ... 11 months in Tygerberg, South Africa in collaboration ...
... comes to talking to parents about most dating issues, teen girls ... to talk to their mothers. However, a new study found ... and what they do with their dates while unsupervised. And in ... mothers than they were their fathers. Results showed that ...
... ... Americans struggling to find steady employment in a highly competitive market. In order to gain ... a more youthful, refreshed appearance. Non-surgical med spa treatments can offer many benefits during a ... (PRWEB) May ...
Cached Medicine News:Health News:Scientists Map Neanderthal Genome 2Health News:Scientists Map Neanderthal Genome 3Health News:Genome breakthrough allows scientists to identify and profile tumor cells from very small samples 2Health News:CWRU global TB expert receives prestigious Fulbright Scholar Award 2Health News:CWRU global TB expert receives prestigious Fulbright Scholar Award 3Health News:Teen girls talk more to parents about their dating habits than do boys 2Health News:Teen girls talk more to parents about their dating habits than do boys 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... Nov. 24, 2014  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 3, 2014 at The New ... . A live webcast of the Company,s presentation ... feature an overview of the company by Pat Mackin ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
... VICTORIA, Australia, April 19, 2011 Genetic Technologies ... executed a preliminary research collaboration agreement to jointly develop ... world,s leading pharmaceutical companies. Under the ... property to work with this world-leading pharmaceutical company to ...
... DALLAS, April 19, 2011 GHX ... Tom Daschle addressed an audience of over 600 healthcare business ... and delivering a sustainable healthcare system at the opening keynote ... The three-day event is focused on the future of the ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2Getting Healthcare Reform Done with the Entire Supply Chain 2Getting Healthcare Reform Done with the Entire Supply Chain 3Getting Healthcare Reform Done with the Entire Supply Chain 4
... 1064 nm Nd:YAG Base Platform ... ophthalmologists treating the anterior segment ... the elimination of secondary cataracts ... Selecta platform offers multiple upgrade ...
... The Alliance Catheter Delivery System ... and stabilization of the Aescula ... CDS has a patented coronary ... quick and easy access to ...
... system is Haemonetics latest ... of plasma and flexible ... collection of "jumbo" units ... plasma with optional saline ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
Medicine Products: